Nexus CMC Advisors
About Nexus CMC Advisors

Focused expertise.Senior regulatory CMC guidance.

Nexus CMC Advisors helps biotech and pharmaceutical teams plan, assess, and document the CMC elements of their development programs.

Our company

A specialized regulatory CMC advisory firm.

Nexus CMC Advisors | Established 2024

Nexus CMC Advisors provides regulatory CMC strategy and submission support for small-molecule, peptide, and oligonucleotide therapeutics. Founded in 2024, the firm draws on its founder's prior experience in pharmaceutical development and regulatory review.

Our work connects the scientific and regulatory sides of CMC — analytical methods, manufacturing and control strategy, stability, and the documentation that supports them — so technical decisions are made with their regulatory implications in view.

Focused specialization

Regulatory CMC strategy for small molecules, peptides, and oligonucleotides — a defined specialty, not a general consulting practice.

Direct senior-level engagement

Engagements are led directly by senior regulatory CMC expertise from scoping through delivery.

Prioritized recommendations

Findings are ranked by regulatory impact and timing, so teams know which CMC issues to resolve first.

Our focus

Built for teams navigating complex development.

Who we support

Emerging biotech companies, virtual pharmaceutical companies, and lean regulatory CMC functions that rely on external manufacturing and testing partners.

How we partner

Advisory engagements scoped to specific milestones — a risk assessment, an IND, or ongoing CMC leadership — with direct access to senior expertise throughout.

Automated synthesis workstation with reagent bottles and tubing
How we work

A structured, collaborative process.

  1. Understand the challenge

    Review your program, data, and development plan to define the CMC questions that matter for the next milestone.

  2. Define the strategy

    Build a phase-appropriate approach that addresses CMC risk, regulatory expectations, and partner deliverables.

  3. Support execution

    Provide continued guidance through development and submission activities, including review of partner and regulatory documentation.

Professional endorsements

Trusted for the Expertise. Valued for the Partnership.

This feedback reflects Paris Hamilton's professional work in roles held before he founded Nexus CMC Advisors.

We were weeks behind on CMC sections for our IND and unsure what was missing. Paris quickly assessed the gaps, helped align our CDMO and internal teams, and got us back on track. His calm, methodical style really stood out.

CMC Program Manager
Small Oncology Biotech

Paris was instrumental in helping us prepare for our FDA pre-IND meeting. His ability to frame our CMC risks and mitigation strategies made the conversation smoother — and the agency’s response more favorable.

Regulatory Affairs Director
Rare Disease Biotech

Most consultants just focus on the immediate deliverables. Paris helped us see how early decisions could impact future phases. That strategic thinking is what makes him a long-term asset.

VP, Clinical Development
Immunology Startup

Paris helped us think through a clear, phase-appropriate CMC plan. As a virtual team, we needed someone who could not only guide CDMOs but also anticipate what regulators would flag. His support made our IND process far less stressful.

Head of R&D
CNS-focused Biotech Startup

Individual feedback from prior professional roles. Not testimonials from Nexus engagements, and not the views of the commenters' employers.

Careers & Opportunities

Interested in working with Nexus?

Current opportunities are listed on LinkedIn. We also welcome interest from experienced regulatory CMC professionals for project-based consulting engagements.

Careers & Opportunities
Scoping call

Discuss your CMC priorities with Nexus.

Schedule a Scoping Call